Surveillance of transmitted HIV-1 drug resistance in gauteng and kwazulu-natal provinces, South Africa, 2005-2009

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Hunt, G M ^a   Ledwaba, J ^a   Basson, A E ^a   Moyes, J ^a   Cohen, C ^a   Singh, B ^a   Bertagnolio, S ^b   Jordan, M R ^b,c   Puren, A ^a   Morris, L ^a  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ADULT; DISEASE SURVEILLANCE; DRUG CLASSIFICATION; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SOUTH AFRICA; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; SOUTH AFRICA;

EID: 84860377749     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir1017     Document Type: Review

References (21)

1. World Health Organization.WHO progress report, 2010. Available at: http://www.who.int/hiv/pub/2010progressreport/ch4-en.pdf.Accessed 15 July 2011.
2. Department of Health. National HIV and syphilis antenatal seroprevalence survey in South Africa. Pretoria, South Africa: Epidemiology and Surveillance Directorate, Department of Health, 2005.
3. Department of Health. National HIV and syphilis antenatal seroprevalence survey in South Africa. Pretoria, South Africa: Epidemiology and Surveillance Directorate, Department of Health, 2009.
4. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13. (Pubitemid 352019085)
5. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13(Suppl 2):25-36. (Pubitemid 352019087)
6. De Luca A, Prosperi M, Bracciale L. Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options. Curr Opin HIV AIDS 2010; 5:27-37.
7. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng province, South Africa in 2002 and 2004. Antivir Ther 2008; 13(Suppl 2):101-7. (Pubitemid 352019096)
8. Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002; 18:295-307. (Pubitemid 34253148)
9. McDougal JS, Parekh BS, Peterson ML, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 2006; 22:945-52. (Pubitemid 46100678)
10. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002.
11. Taylor BS, Hunt G, Abrams EJ, et al. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses 2011; 27:945-56.
12. Gifford RJ, Liu TF, Rhee SY, et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009; 25:1197-8.
13. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
14. Marconi VC, SunpathH, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-97. (Pubitemid 351706742)
15. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a crosssectional study in Soweto, South Africa. AIDS 2010; 24:1679-87.
16. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-31.
17. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-4.
18. Hargrove JW, Humphrey JH, Mutasa K, et al. Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 2008; 22:511-8. (Pubitemid 351317293)
19. Vercauteren J, Wensing AM, van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-8.
20. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U. S.-2006. AIDS 2010; 24:1203-12.
21. Ndembi N, Hamers RL, Sigaloff KC, et al. Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 2011; 25:905-10.